Judge Vacates $140 Million Verdict In Testosterone Lawsuit

https://www.hghprescription.com/testosterone-therapy/judge-vacates-140-million-verdict-in-testosterone-lawsuit

A federal judge has vacated a massive 140 million dollar verdict over testosterone replacement therapy (TRT) treatment after concluding that the jury’s finding was inconsistent.

The lawsuit was filed by Jeffrey Konrad, a Tennessee resident. Konrad claimed in his filing that he suffered a heart attack after two months of testosterone therapy using AndroGel, a topical gel that is used to treat low testosterone (“Low-T”) in older men.

AndroGel is manufactured by the large Chicago-based pharmaceutical company AbbVie.

In October 2017, a jury awarded Konrad $140,000 in compensatory damages and $140 million in punitive damages after finding that AbbVie was negligent and misrepresented the possible adverse side effects of AndroGel. Konrad claimed that AndroGel was directly responsible for his heart attack.

However, Chicago U.S. District Judge Matthew Kennelly ordered a retrial of the lawsuit. Kennelly stated that the jury’s finding on the negligent claim was inconsistent with its decision to find AbbVie not liable on a different issue as both claims involved determining if AndroGel was extremely and exceptionally dangerous -- and thus provoked his heart attack.